Posted 3/13/2017 4:37 PM (GMT 0)
Since I started this current flare a month ago, my GI has been trying every possible line of treatment to put symptoms at bay. I saw him again after a week as pain has become unbearable. After examination, he decided my disease is active. So, he took some measures: upped Entocort to 6 mg and decided to let me have Remicade every 4 weeks instead of 6. I'll continue taking both the antispasmodic and painkiller till the infusion is due. I argued about taking the painkiller but he insisted as pain hits me once the effect of both the antispasmodic and painkiller wears off.
My question is: My GI suggested we measure both Remicade trough level and antibodies prior to next infusion. Would shortening the time interval show a high tough level or aren't they related? The last dose I took on the 1st of March did not work at all and that's why I'm suffering. We can't figure out the cause I relapsed. It could be that my disease since it is active this time is more aggressive than Remicade or because it happened that Imuran was not available in my country so I had to lower the dose. My GI says it could be a plausible justification and I still need like a month for it to start working and it could be the cause of the replase. Another reason could be the antibiotic I was given when they suspected malignancy and it immediately threw me into a flare up. Or could just be simply a combination of all the aforementioned causes. Or ... or it could be that I developed antibodies which my doctor was not at ease when I asked him about and that's why he suggested we have the tests done.
Is it ok if after 4 weeks they find that the trough level is high and do they overlook it if the main target is putting the flare up at bay? When I last had the trough test level done, it was 7.2 in week 5. My GI told me then it should be lower than 10 but he'd rather I have a level of 5 or 6 so we pushed it till week 6. Or would a flare up be eating up Infliximab and thus yield lower levels? All these are questions if I have not (hopefully) developed antibodies. There are still a lot of ambiguities about Infliximab that I try to understand.